R. McGovern

发表

The use of genetic sequencing technologies to determine HIV-1 viral tropism and to evaluate the effects of maraviroc on patient viral populations

R. McGovern, 2015 .

Factors Influencing the Sensitivity and Specificity of Conventional Sequencing in Human Immunodeficiency Virus Type 1 Tropism Testing

P. Harrigan, D. Knapp, A. Poon, 2012, Journal of Clinical Microbiology.

Mutations in Gp41 are Correlated with Coreceptor Tropism but Do Not Improve Prediction Methods Substantially

Thomas Lengauer, P. Harrigan, H. Valdez, 2011, Antiviral therapy.

Uncommon Pathways of Immune Escape Attenuate HIV-1 Integrase Replication Capacity

D. Heckerman, E. Rosenberg, H. Jessen, 2012, Journal of Virology.

Population-Based Sequencing of the V3-loop Can Predict the Virological Response to Maraviroc in Treatment-Naive Patients of the MERIT Trial

P. Harrigan, H. Valdez, A. Thielen, 2012, Journal of acquired immune deficiency syndromes.

Correlation of the Virological Response to Short-Term Maraviroc Monotherapy with Standard and Deep-Sequencing-Based Genotypic Tropism Prediction Methods

P. Harrigan, A. Poon, E. Ruiz-Mateos, 2011, Antimicrobial Agents and Chemotherapy.

Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies

P. Harrigan, H. Valdez, A. Thielen, 2010, AIDS.

Genotypic determination of HIV-1 tropism in the clinical setting

P. Harrigan, A. Thielen, L. C. Swenson, 2010 .

Genotypic inference of HIV-1 tropism using population-based sequencing of V3.

P. Harrigan, L. C. Swenson, R. McGovern, 2010, Journal of visualized experiments : JoVE.

Trofile HIV co-receptor usage assay.

Andrew J. Low, P. Harrigan, Andrew J Low, 2009, Expert opinion on medical diagnostics.

Early immune adaptation in HIV-1 revealed by population-level approaches

Todd M. Allen, H. Jessen, T. Allen, 2014, Retrovirology.

Temporal trends in the discontinuation of first-line antiretroviral therapy.

B. Yip, R. Hogg, R. Harrigan, 2014, The Journal of antimicrobial chemotherapy.

“Deep” Sequencing Accuracy and Reproducibility Using Roche/454 Technology for Inferring Co-Receptor Usage in HIV-1

P. Harrigan, D. Knapp, A. Poon, 2014, PloS one.

Post-Marketing Experience with Nevirapine Extended Release (XR) Tablets: Effectiveness and Tolerability in a Population-Based Cohort in British Columbia, Canada

P. Harrigan, B. Yip, R. Hogg, 2015, Antiviral therapy.

Dates of HIV infection can be estimated for seroprevalent patients by coalescent analysis of serial next-generation sequencing data

Art F Y Poon, Bluma Brenner, David J H F Knapp, 2011, AIDS.

Early immune adaptation in HIV-1 revealed by population-level approaches

Todd M. Allen, H. Jessen, M. Carrington, 2014, Retrovirology.

Screening for HIV Tropism Using Population-based V3 Genotypic Analysis: A Retrospective Outcome Analysis Using Stored Plasma Screening Samples from MOTIVATE-1

M. Jensen, P. Harrigan, H. Valdez, 2009 .

Maraviroc treatment in non-R5-HIV-1-infected patients results in the selection of extreme CXCR4-using variants with limited effect on the total viral setpoint.

P. Harrigan, A. Poon, A. Wensing, 2013, The Journal of antimicrobial chemotherapy.

Uncommon Pathways of Immune Escape Attenuate HIV-1 Integrase Replication Capacity

D. Heckerman, E. Rosenberg, H. Jessen, 2012, Journal of Virology.